Arecor Therapeutics (LSE:AREC) GF Score: 37/100 (As of Aug. 01, 2026) — 106% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:AREC Arecor Therapeutics PLC LSE:AREC
37 GF Score
Price £0.61
GF Value £0.44
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics GF Score?

Arecor Therapeutics LSE:AREC -3.94% 37 GF Score is 37 as of Aug. 01, 2026, which is 106% above its 10-year median of 18.00. GuruFocus rates LSE:AREC with a GF Score™ of 37/100 and a GF Value™ of £0.44 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Arecor Therapeutics has the GF Score of 37, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 1/10
3. Growth Rank : 1/10
4. GF Value Rank : 3/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Arecor Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Arecor Therapeutics  (LSE:AREC) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Arecor Therapeutics GF Score Related Terms

LSE:AREC vs VRTX, REGN, RVMD: GF Score Comparison

For the Biotechnology subindustry, Arecor Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arecor Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's GF Score falls into.


LSE:AREC
37GF Score
Arecor Therapeutics PLC LSE:AREC
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 37 mean?
Arecor Therapeutics (LSE:AREC) has a GF Score of 37 as of Aug. 01, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Arecor Therapeutics and its competitors. This is 106% above median its historical median of 18.00. Over the past decade, Arecor Therapeutics' GF Score has ranged from 9.00 to 65.00.
Is Arecor Therapeutics' GF Score too high?
Arecor Therapeutics' current GF Score of 37 is 106% above median its 10-year median of 18.00. Over the past 10 years, this metric has ranged from a low of 9.00 to a high of 65.00. Overall, Arecor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' GF Score compare to VRTX and REGN?
Arecor Therapeutics' GF Score of 37 can be compared against companies in the Biotechnology industry. Historically, Arecor Therapeutics' own GF Score has ranged from 9.00 to 65.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Arecor Therapeutics and its competitors. Arecor Therapeutics's current GF Score is 37, which is 106% above median its own 10-year median of 18.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Arecor Therapeutics (LSE:AREC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.44, compared to a current price of £0.61 — trading 38.6% above its estimated fair value. The current GF Score is 37, which is 106% above median its 10-year median of 18.00. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Arecor Therapeutics (LSE:AREC), the current GF Score is 37 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arecor Therapeutics (LSE:AREC) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of £0.61 is trading 38.6% above its estimated GF Value™ of £0.44. GuruFocus considers Arecor Therapeutics to be Significantly Overvalued.

Key valuation signals for LSE:AREC:

  • GF Score: 37 (106% above median its 10-year median of 18.00)
  • GF Value™: £0.44 vs. price of £0.61 (38.6% above fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the LSE:AREC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arecor Therapeutics Business Description

Other Exchanges 6UI:Germany
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score

Get the complete analysis for LSE:AREC

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.61
Price
£0.44
GF Value